Bolon Maureen K, Wright Sharon B, Gold Howard S, Carmeli Yehuda
Division of Infectious Diseases, Beth Israel Deaconess Medical Center Boston, Massachusetts, USA.
Antimicrob Agents Chemother. 2004 Jun;48(6):1934-40. doi: 10.1128/AAC.48.6.1934-1940.2004.
Case-control analyses of resistant versus susceptible isolates have implicated fluoroquinolone exposure as a strong risk factor for fluoroquinolone-resistant isolates of Enterobacteriaceae. We suspect that such methodology may overestimate this association. A total of 84 cases with fluoroquinolone-resistant isolates and 578 cases with fluoroquinolone-susceptible isolates of Escherichia coli or Klebsiella pneumoniae were compared with 608 hospitalized controls in parallel multivariable analyses. For comparison of previous estimates, the results of 10 published case-control studies of risk for fluoroquinolone resistance in isolates of Enterobacteriaceae were pooled by using a random-effects model. Exposure to fluoroquinolones was significantly positively associated with fluoroquinolone resistance (odds ratio [OR], 3.17) and negatively associated with fluoroquinolone susceptibility (OR, 0.18). Multivariable analyses yielded similar estimates (ORs, 2.04 and 0.10, respectively). As data on antibiotic exposure were limited to inpatient prescriptions, misclassification of fluoroquinolone exposure in persons who received fluoroquinolones as outpatients may have led to an underestimation of the true effect size. Pooling the results of previously published studies in which a direct comparison of fluoroquinolone-resistant and fluoroquinolone-susceptible cases was used resulted in a markedly higher effect estimate (OR, 18.7). Had we directly compared resistant and susceptible cases, our univariate OR for the association between fluoroquinolone use and the isolation of resistant Enterobacteriaceae would have been 19.3, and the multivariate OR would have been 16.5. Fluoroquinolone use is significantly associated with the isolation of fluoroquinolone-resistant Enterobacteriaceae; however, previous studies likely exaggerated the magnitude of this association.
针对耐药菌株与敏感菌株的病例对照分析表明,氟喹诺酮类药物暴露是肠杆菌科细菌对氟喹诺酮耐药的一个重要危险因素。我们怀疑这种方法可能高估了这种关联。在平行多变量分析中,将84例携带耐氟喹诺酮菌株的病例以及578例携带对氟喹诺酮敏感的大肠杆菌或肺炎克雷伯菌菌株的病例与608例住院对照进行了比较。为了比较之前的估计值,采用随机效应模型汇总了10项已发表的关于肠杆菌科细菌对氟喹诺酮耐药风险的病例对照研究结果。氟喹诺酮类药物暴露与氟喹诺酮耐药显著正相关(比值比[OR],3.17),与氟喹诺酮敏感性负相关(OR,0.18)。多变量分析得出了类似的估计值(分别为OR,2.04和0.10)。由于抗生素暴露数据仅限于住院处方,门诊接受氟喹诺酮类药物治疗的患者中氟喹诺酮暴露的错误分类可能导致对真实效应大小的低估。汇总之前发表的使用耐氟喹诺酮和对氟喹诺酮敏感病例直接比较的研究结果,得到的效应估计值明显更高(OR,18.7)。如果我们直接比较耐药和敏感病例,氟喹诺酮使用与耐氟喹诺酮肠杆菌科细菌分离之间关联的单变量OR将为19.3,多变量OR将为16.5。氟喹诺酮类药物的使用与耐氟喹诺酮肠杆菌科细菌的分离显著相关;然而,之前的研究可能夸大了这种关联的程度。